NR-546: Advanced Psychopharmacology for the PMHNP
Final Exam Question Bank
Course Code: NR-546
Course Name: Advanced Psychopharmacology for the PMHNP (Final Exam
Study Bank)
Topic: Advanced Neurotransmitter Systems, Receptor Dynamics, and
Clinical Psychopharmacology
Academic Year: 2026/2027
1. A 34-year-old female with a history of Major Depressive Disorder (MDD)
presents with persistent fatigue, low energy, and poor concentration. She has
been on a therapeutic dose of an SSRI for 12 weeks with only minimal
, improvement. The PMHNP decides to initiate bupropion as an augmenting
agent. Which mechanism of action explains the therapeutic synergy of this
pharmacological addition?
A. Potent serotonin 2A 5HT2A receptor antagonism combined with MAO-B
inhibition.
B. Inhibition of the Norepinephrine Transporter (NET) and Dopamine
Transporter (DAT), increasing norepinephrine and dopamine levels in
the prefrontal cortex.
C. Selective antagonism of central alpha-2 adrenergic auto-receptors,
accelerating serotonin release.
D. Modulatory enhancement of GABA-A receptor chlorine channels leading
to rapid anxiolysis.
CORRECT ANSWER: B
RATIONALE: Bupropion is a Norepinephrine-Dopamine Reuptake
Inhibitor (NDRI). By blocking the reuptake of norepinephrine via NET and
dopamine via DAT, it increases the synaptic availability of these
catecholamines in the prefrontal cortex. This specific neurochemical action
targets symptoms of "decreased positive affect," such as fatigue, anhedonia,
and poor concentration, which are often left unaddressed by pure SSRIs.
Distractor A is incorrect because bupropion has no direct effect on serotonin
receptors or MAO enzymes. Distractor C describes the mechanism of
mirtazapine. Distractor D describes the mechanism of benzodiazepines.
2. A 22-year-old male diagnosed with Schizophrenia is brought to the clinic
for a routine follow-up. He has been taking a first-generation antipsychotic,
haloperidol, for 6 months. During the assessment, the PMHNP observes
involuntary, rhythmic movements of the patient's tongue, facial grimacing,
and lip-smacking. What is the underlying neurochemistry driving this
Tardive Dyskinesia (TD) presentation?
A. Acute hyper-activation of cholinergic muscarinic receptors in the nucleus
accumbens.
B. Up-regulation and supersensitivity of Dopamine D2 receptors in the
nigrostriatal pathway following chronic, prolonged receptor blockade.
C. Severe depletion of serotonin reserves within the dorsal raphe nucleus.
D. Direct neurotoxic destruction of GABAergic interneurons in the frontal
motor cortex.
, CORRECT ANSWER: B
RATIONALE: Tardive Dyskinesia (TD) is a late-onset
extrapyramidal symptom (EPS) caused by chronic exposure to
antipsychotics that heavily block D2 receptors, particularly first-generation
antipsychotics like haloperidol. Over time, the continuous blockade leads to
a compensatory up-regulation and postsynaptic supersensitivity of D2
receptors in the nigrostriatal pathway. When dopamine interacts with
these hyper-responsive receptors, it causes hyperkinetic movements.
Distractor A describes cholinergic changes, which are typically associated
with acute dystonia or parkinsonism where acetylcholine is unchecked.
Distractors C and D misidentify the primary neuroanatomical tracts and
neurotransmitters involved.
3. A 45-year-old male presents with severe Generalized Anxiety Disorder
(GAD). He has a documented history of severe alcohol use disorder and has
been sober for 18 months. The PMHNP wants to avoid benzodiazepines due
to the risk of dependence. Which non-benzodiazepine anxiolytic agent acts
as a Serotonin 5HT1A receptor partial agonist and is appropriate for long-
term anxiety management in this patient?
A. Hydroxyzine
B. Alprazolam
C. Buspirone
D. Clonidine
CORRECT ANSWER: C
RATIONALE: Buspirone is an effective, non-benzodiazepine
anxiolytic that operates as a partial agonist at pre- and postsynaptic
Serotonin receptors 5HT1A. Because it does not interact directly with the
GABA-A receptor complex, it lacks the sedative, muscle-relaxant, and
dependency-inducing properties of benzodiazepines, making it a safe choice
for a patient with a history of substance use disorder. Distractor A is an
antihistamine (H₁ antagonist). Distractor B is a benzodiazepine, which is
contraindicated due to substance history. Distractor D is an alpha-2 agonist
used off-label for autonomic hyperarousal.
4. A 19-year-old female college student is diagnosed with Bipolar I Disorder
after experiencing a classic manic episode. The PMHNP chooses to initiate
lithium therapy. When educating the patient on this medication, which
, physiological mechanism must be explained regarding how lithium handles
intracellular messaging loops?
A. Direct activation of voltage-gated calcium channels via the NMDA
receptor.
B. Inhibition of the second messenger enzyme glycogen synthase kinase-
3 (GSK-3) and the inositol monophosphatase (IMPase) pathway,
stabilizing downstream intracellular signaling.
C. Blockade of the vesicular monoamine transporter 2 (VMAT2), trapping
serotonin in vesicles.
D. Allosteric modulation of the alpha subunit of the GABA receptor.
CORRECT ANSWER: B
RATIONALE: While the exact therapeutic mechanism of lithium is
multi-faceted, its primary established intracellular actions involve inhibiting
key second messenger enzymes, specifically Glycogen Synthase Kinase-3
(GSK-3) and Inositol Monophosphatase (IMPase). By dampening the
overactive inositol signaling cycle and modulating GSK-3, lithium exerts
neuroprotective effects and stabilizes monoaminergic and glutamatergic
signaling loops, helping to prevent both manic and depressive swings.
Distractors A, C, and D describe properties of other drug classes (e.g.,
VMAT2 is targeted by valbenazine; GABA is targeted by sedatives).
5. A 68-year-old male with a history of moderate Alzheimer's dementia is
experiencing progressive cognitive decline. The PMHNP decides to
prescribe memantine as an add-on to his current acetylcholinesterase
inhibitor regimen. Which neuroprotective mechanism describes the action of
memantine?
A. High-affinity irreversible binding to postsynaptic nicotinic receptors.
B. Uncompetitive, low-affinity NMDA receptor antagonism that blocks
pathological tonic levels of glutamate while preserving normal
physiological bursts required for learning.
C. Selective inhibition of butyrylcholinesterase lines within the cerebral
vasculature.
D. Direct upregulation of brain-derived neurotrophic factor (BDNF)
transcriptions.
CORRECT ANSWER: B
RATIONALE: In Alzheimer's disease, chronic overactivation of
Final Exam Question Bank
Course Code: NR-546
Course Name: Advanced Psychopharmacology for the PMHNP (Final Exam
Study Bank)
Topic: Advanced Neurotransmitter Systems, Receptor Dynamics, and
Clinical Psychopharmacology
Academic Year: 2026/2027
1. A 34-year-old female with a history of Major Depressive Disorder (MDD)
presents with persistent fatigue, low energy, and poor concentration. She has
been on a therapeutic dose of an SSRI for 12 weeks with only minimal
, improvement. The PMHNP decides to initiate bupropion as an augmenting
agent. Which mechanism of action explains the therapeutic synergy of this
pharmacological addition?
A. Potent serotonin 2A 5HT2A receptor antagonism combined with MAO-B
inhibition.
B. Inhibition of the Norepinephrine Transporter (NET) and Dopamine
Transporter (DAT), increasing norepinephrine and dopamine levels in
the prefrontal cortex.
C. Selective antagonism of central alpha-2 adrenergic auto-receptors,
accelerating serotonin release.
D. Modulatory enhancement of GABA-A receptor chlorine channels leading
to rapid anxiolysis.
CORRECT ANSWER: B
RATIONALE: Bupropion is a Norepinephrine-Dopamine Reuptake
Inhibitor (NDRI). By blocking the reuptake of norepinephrine via NET and
dopamine via DAT, it increases the synaptic availability of these
catecholamines in the prefrontal cortex. This specific neurochemical action
targets symptoms of "decreased positive affect," such as fatigue, anhedonia,
and poor concentration, which are often left unaddressed by pure SSRIs.
Distractor A is incorrect because bupropion has no direct effect on serotonin
receptors or MAO enzymes. Distractor C describes the mechanism of
mirtazapine. Distractor D describes the mechanism of benzodiazepines.
2. A 22-year-old male diagnosed with Schizophrenia is brought to the clinic
for a routine follow-up. He has been taking a first-generation antipsychotic,
haloperidol, for 6 months. During the assessment, the PMHNP observes
involuntary, rhythmic movements of the patient's tongue, facial grimacing,
and lip-smacking. What is the underlying neurochemistry driving this
Tardive Dyskinesia (TD) presentation?
A. Acute hyper-activation of cholinergic muscarinic receptors in the nucleus
accumbens.
B. Up-regulation and supersensitivity of Dopamine D2 receptors in the
nigrostriatal pathway following chronic, prolonged receptor blockade.
C. Severe depletion of serotonin reserves within the dorsal raphe nucleus.
D. Direct neurotoxic destruction of GABAergic interneurons in the frontal
motor cortex.
, CORRECT ANSWER: B
RATIONALE: Tardive Dyskinesia (TD) is a late-onset
extrapyramidal symptom (EPS) caused by chronic exposure to
antipsychotics that heavily block D2 receptors, particularly first-generation
antipsychotics like haloperidol. Over time, the continuous blockade leads to
a compensatory up-regulation and postsynaptic supersensitivity of D2
receptors in the nigrostriatal pathway. When dopamine interacts with
these hyper-responsive receptors, it causes hyperkinetic movements.
Distractor A describes cholinergic changes, which are typically associated
with acute dystonia or parkinsonism where acetylcholine is unchecked.
Distractors C and D misidentify the primary neuroanatomical tracts and
neurotransmitters involved.
3. A 45-year-old male presents with severe Generalized Anxiety Disorder
(GAD). He has a documented history of severe alcohol use disorder and has
been sober for 18 months. The PMHNP wants to avoid benzodiazepines due
to the risk of dependence. Which non-benzodiazepine anxiolytic agent acts
as a Serotonin 5HT1A receptor partial agonist and is appropriate for long-
term anxiety management in this patient?
A. Hydroxyzine
B. Alprazolam
C. Buspirone
D. Clonidine
CORRECT ANSWER: C
RATIONALE: Buspirone is an effective, non-benzodiazepine
anxiolytic that operates as a partial agonist at pre- and postsynaptic
Serotonin receptors 5HT1A. Because it does not interact directly with the
GABA-A receptor complex, it lacks the sedative, muscle-relaxant, and
dependency-inducing properties of benzodiazepines, making it a safe choice
for a patient with a history of substance use disorder. Distractor A is an
antihistamine (H₁ antagonist). Distractor B is a benzodiazepine, which is
contraindicated due to substance history. Distractor D is an alpha-2 agonist
used off-label for autonomic hyperarousal.
4. A 19-year-old female college student is diagnosed with Bipolar I Disorder
after experiencing a classic manic episode. The PMHNP chooses to initiate
lithium therapy. When educating the patient on this medication, which
, physiological mechanism must be explained regarding how lithium handles
intracellular messaging loops?
A. Direct activation of voltage-gated calcium channels via the NMDA
receptor.
B. Inhibition of the second messenger enzyme glycogen synthase kinase-
3 (GSK-3) and the inositol monophosphatase (IMPase) pathway,
stabilizing downstream intracellular signaling.
C. Blockade of the vesicular monoamine transporter 2 (VMAT2), trapping
serotonin in vesicles.
D. Allosteric modulation of the alpha subunit of the GABA receptor.
CORRECT ANSWER: B
RATIONALE: While the exact therapeutic mechanism of lithium is
multi-faceted, its primary established intracellular actions involve inhibiting
key second messenger enzymes, specifically Glycogen Synthase Kinase-3
(GSK-3) and Inositol Monophosphatase (IMPase). By dampening the
overactive inositol signaling cycle and modulating GSK-3, lithium exerts
neuroprotective effects and stabilizes monoaminergic and glutamatergic
signaling loops, helping to prevent both manic and depressive swings.
Distractors A, C, and D describe properties of other drug classes (e.g.,
VMAT2 is targeted by valbenazine; GABA is targeted by sedatives).
5. A 68-year-old male with a history of moderate Alzheimer's dementia is
experiencing progressive cognitive decline. The PMHNP decides to
prescribe memantine as an add-on to his current acetylcholinesterase
inhibitor regimen. Which neuroprotective mechanism describes the action of
memantine?
A. High-affinity irreversible binding to postsynaptic nicotinic receptors.
B. Uncompetitive, low-affinity NMDA receptor antagonism that blocks
pathological tonic levels of glutamate while preserving normal
physiological bursts required for learning.
C. Selective inhibition of butyrylcholinesterase lines within the cerebral
vasculature.
D. Direct upregulation of brain-derived neurotrophic factor (BDNF)
transcriptions.
CORRECT ANSWER: B
RATIONALE: In Alzheimer's disease, chronic overactivation of
